81 related articles for article (PubMed ID: 33260179)
1. Personalized Medicine and Cervical Screening: Development of Individualized Quantitative Risk Assessments for Cervical Adenocarcinoma and Adenocarcinoma in situ.
Jones TE; Onisko A; Austin RM
Acta Cytol; 2021; 65(2):158-164. PubMed ID: 33260179
[TBL] [Abstract][Full Text] [Related]
2. Severe cervical glandular cell lesions and severe cervical combined lesions: predictive value of the papanicolaou smear.
van Aspert-van Erp AJ; Smedts FM; Vooijs GP
Cancer; 2004 Aug; 102(4):210-7. PubMed ID: 15368312
[TBL] [Abstract][Full Text] [Related]
3. Cervical screening test results associated with 265 histopathologic diagnoses of cervical glandular neoplasia.
Zhao C; Li Z; Austin RM
Am J Clin Pathol; 2013 Jul; 140(1):47-54. PubMed ID: 23765533
[TBL] [Abstract][Full Text] [Related]
4. Cervical Screening Results Leading to Detection of Adenocarcinoma in Situ of the Uterine Cervix.
Srisomboon S; Tantipalakorn C; Charoenkwan K; Srisomboon J
Asian Pac J Cancer Prev; 2019 Feb; 20(2):377-382. PubMed ID: 30803195
[TBL] [Abstract][Full Text] [Related]
5. Preinvasive and Invasive Cervical Adenocarcinoma: Preceding Low-Risk or Negative Pap Result Increases Time to Diagnosis.
Moukarzel LA; Angarita AM; VandenBussche C; Rositch A; Thompson CB; Fader AN; Levinson K
J Low Genit Tract Dis; 2017 Apr; 21(2):91-96. PubMed ID: 27977543
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus (HPV) test and PAP smear as predictors of outcome in conservatively treated adenocarcinoma in situ (AIS) of the uterine cervix.
Costa S; Negri G; Sideri M; Santini D; Martinelli G; Venturoli S; Pelusi C; Syrjanen S; Syrjanen K; Pelusi G
Gynecol Oncol; 2007 Jul; 106(1):170-6. PubMed ID: 17481701
[TBL] [Abstract][Full Text] [Related]
7. Individualized Bayesian Risk Assessment for Cervical Squamous Neoplasia.
Farchoukh LF; Onisko A; Austin RM
J Pathol Inform; 2020; 11():9. PubMed ID: 32477615
[TBL] [Abstract][Full Text] [Related]
8. RANZCOG Fellows' adherence to guidelines following cytological prediction of cervical adenocarcinoma-in-situ: Cause for concern?
Powell A; Cohen PA; Spilsbury K; Steel N; Blomfield P
Aust N Z J Obstet Gynaecol; 2019 Apr; 59(2):294-300. PubMed ID: 30284744
[TBL] [Abstract][Full Text] [Related]
9. Age-specific 3-year cumulative risk of cervical cancer and high-grade dysplasia on biopsy in 9434 women who underwent HPV cytology cotesting.
Ge Y; Christensen PA; Luna E; Armylagos D; Xu J; Hsu JW; Zhou H; Schwartz MR; Mody DR
Cancer Cytopathol; 2019 Dec; 127(12):757-764. PubMed ID: 31589379
[TBL] [Abstract][Full Text] [Related]
10. HPV-ISH-Negative Invasive Cervical Squamous Cell Carcinoma: Histologic and Pap Test Results.
Alexander C; White M; Maleki Z; Rodriguez EF
Acta Cytol; 2019; 63(5):417-423. PubMed ID: 31195388
[TBL] [Abstract][Full Text] [Related]
11. Severe cervical glandular cell lesions with coexisting squamous cell lesions.
van Aspert-van Erp AJ; Smedts FM; Vooijs GP
Cancer; 2004 Aug; 102(4):218-27. PubMed ID: 15368313
[TBL] [Abstract][Full Text] [Related]
12. Glandular Lesions of the Cervix in Clinical Practice: A Cytology, Histology, and Human Papillomavirus Correlation Study From 2 Institutions.
Miller RA; Mody DR; Tams KC; Thrall MJ
Arch Pathol Lab Med; 2015 Nov; 139(11):1431-6. PubMed ID: 25951104
[TBL] [Abstract][Full Text] [Related]
13. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study.
Malagón T; Kulasingam S; Mayrand MH; Ogilvie G; Smith L; Bouchard C; Gotlieb W; Franco EL
Lancet Oncol; 2018 Dec; 19(12):1569-1578. PubMed ID: 30392810
[TBL] [Abstract][Full Text] [Related]
14. Prior high-risk HPV testing and Pap test results for 427 invasive cervical cancers in China's largest CAP-certified laboratory.
Zheng B; Li Z; Griffith CC; Yan S; Chen C; Ding X; Liang X; Yang H; Zhao C
Cancer Cytopathol; 2015 Jul; 123(7):428-34. PubMed ID: 25954852
[TBL] [Abstract][Full Text] [Related]
15. Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study.
Wang J; Andrae B; Sundström K; Ström P; Ploner A; Elfström KM; Arnheim-Dahlström L; Dillner J; Sparén P
BMJ; 2016 Feb; 352():i276. PubMed ID: 26869597
[TBL] [Abstract][Full Text] [Related]
16. False-negative Papanicolaou tests in women with biopsy-proven invasive endocervical adenocarcinoma/adenocarcinoma in situ: a retrospective analysis with assessment of interobserver agreement.
Lin M; Narkcham S; Jones A; Armylagos D; DiPietro B; Okafor O; Tracey P; Vercher T; Vasquez S; Haley S; Crumley S; Gorman B; Jacobi E; Amrikachi M; Coffey D; Mody D; Okoye E
J Am Soc Cytopathol; 2022; 11(1):3-12. PubMed ID: 34583894
[TBL] [Abstract][Full Text] [Related]
17. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
18. The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix.
Zielinski GD; Snijders PJ; Rozendaal L; Daalmeijer NF; Risse EK; Voorhorst FJ; Jiwa NM; van der Linden HC; de Schipper FA; Runsink AP; Meijer CJ
J Pathol; 2003 Dec; 201(4):535-43. PubMed ID: 14648656
[TBL] [Abstract][Full Text] [Related]
19. Age influences the clinical significance of atypical glandular cells on cytology.
Asciutto KC; Henic E; Forslund O; Bjelkenkrantz K; Borgfeldt C
Anticancer Res; 2015 Feb; 35(2):913-9. PubMed ID: 25667474
[TBL] [Abstract][Full Text] [Related]
20. Challenges in the Pap diagnosis of endocervical adenocarcinoma in situ.
Niu S; Molberg K; Thibodeaux J; Rivera-Colon G; Hinson S; Zheng W; Lucas E
J Am Soc Cytopathol; 2019; 8(3):141-148. PubMed ID: 31097290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
